538
Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.
 further decrease the incidence of CNS relapse or to improve the overall DFS: Effect; HD Ara-C: Treatment; HD MTX: Treatment; HD Ara-C: Treatment.Drug; HD MTX: Treatment.Drug; HD Ara-C: Combination.Drug; HD MTX: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 further decrease the incidence of CNS relapse or to improve the overall DFS: Effect; HD Ara-C: Treatment; HD MTX: Treatment; HD Ara-C: Treatment.Drug; HD MTX: Treatment.Drug; HD Ara-C: Combination.Drug; HD MTX: Combination.Drug